Nitric oxide synthase gene therapy (MaxCyte/Northern Therapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameNitric oxide synthase gene therapy (MaxCyte/Northern Therapeutics)
Drug Alias NameeNOS transfected EPCsPulmonary hypertension gene therapy
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionNitric oxide synthase stimulants
TargetsNitric oxide synthase
Therapy Area/IndicationsPulmonary Arterial Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMaxcyte IncNorthern Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNorthern TherapeuticsMaxcyte Inc
Active IndicationsN/A
Inactive IndicationsPulmonary Arterial Hypertension

Other Information

ATC CodeN/A
Related LinksN/A